Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lu AF 28996

Next Previous
Drug Profile

Lu AF 28996

Alternative Names: Lu AF-28996

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 30 Mar 2026 Lu AF 28996 is still in phase I trial in Parkinson's disease (Treatment-experienced) in Japan (PO) (NCT06004180)
  • 30 Mar 2026 Lu AF 28996 is still in phase-I trial for Parkinson's disease (Adjunctive treatment) in Spain, Germany, France, Netherlands, USA (PO) (NCT04291859) (H. Lundbeck pipeline, March 2026)
  • 28 Mar 2026 No recent reports of development identified for phase-I development in Parkinson's-disease(Adjunctive treatment) in France (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top